ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

被引：5
|
作者：
Poei, Darin [1 ]
Ali, Sana [2 ]
Ye, Shirley [1 ]
Hsu, Robert [2 ,3 ]
机构：
[1] Univ Southern Calif, Dept Internal Med, Los Angeles, CA 90033 USA
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA 90033 USA
[3] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Med, Div Med Oncol, 1441 Eastlake Ave, Los Angeles, CA 90033 USA
来源：
CANCER DRUG RESISTANCE | 2024年 / 7卷
关键词：
NSCLC; ALK TKI; acquired resistance; alectinib; crizotinib; lorlatinib; ceritinib; brigatinib; CELL LUNG-CANCER; LYMPHOMA KINASE ALK; GENERATION SEQUENCING REVEALS; PREFERRED 1ST-LINE OPTION; FACTOR RECEPTOR EGFR; OPEN-LABEL; TYROSINE KINASE; PHASE-II; CRIZOTINIB RESISTANCE; ACQUIRED-RESISTANCE;
D O I：
10.20517/cdr.2024.25
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified as potent oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC). The discovery of ALK inhibition using a tyrosine kinase inhibitor (TKI) has dramatically improved the outcomes of patients with ALK-mutated NSCLC. However, the emergence of intrinsic and acquired resistance inevitably occurs with ALK TKI use. This review describes the molecular mechanisms of ALK TKI resistance and discusses management strategies to overcome therapeutic resistance.
引用
收藏
页数：22
相关论文
共 50 条
  • [31] Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer
    Qian, Fang-Fei
    Han, Bao-Hui
    CHINESE MEDICAL JOURNAL, 2020, 133 (20) : 2444 - 2455
  • [32] Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers
    Fuse, Miho J.
    Okada, Koutaroh
    Oh-hara, Tomoko
    Ogura, Hayato
    Fujita, Naoya
    Katayama, Ryohei
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (10) : 2130 - 2143
  • [33] Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies
    Yao, Kun
    Liu, Hua
    Yu, Shui
    Zhu, Haohao
    Pan, Jie
    CANCER LETTERS, 2022, 533
  • [34] RESISTANCE TO ALK INHIBITORS
    Doebele, Robert C.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S91 - S92
  • [35] Proteasome Inhibitors Therapeutic Strategies for Cancer
    D'Alessandro, Annamaria
    Pieroni, Luisa
    Ronci, Maurizio
    D'Aguanno, Simona
    Federici, Giorgio
    Urbani, Andrea
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2009, 4 (01) : 73 - 82
  • [36] Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice
    Jamme, Philippe
    Descarpentries, Clotilde
    Gervais, Radj
    Dansin, Eric
    Wislez, Marie
    Gregoire, Valerie
    Richard, Nicolas
    Baldacci, Simon
    Rabbe, Nathalie
    Kyheng, Maeva
    Kherrouche, Zoulika
    Escande, Fabienne
    Copin, Marie Christine
    Cortot, Alexis B.
    CLINICAL LUNG CANCER, 2019, 20 (04) : 297 - +
  • [37] Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review
    Desai, Aakash
    Lovly, Christine M.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (03) : 615 - 628
  • [38] Insulin Resistance: From Mechanisms to Therapeutic Strategies
    Lee, Shin-Hae
    Park, Shi-Young
    Choi, Cheol Soo
    DIABETES & METABOLISM JOURNAL, 2022, 46 (01) : 15 - 37
  • [39] Detection of Mechanisms of Resistance to ALK Inhibitors in Routine Practice: A Retrospective Study
    Jamme, P.
    Descarpentries, C.
    Wislez, M.
    Dansin, E.
    Gregoire, V.
    Baldacci, S.
    Escande, F.
    Mathiot, N.
    Kyheng, M.
    Kherrouche, Z.
    Copin, M. C.
    Cortot, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1828 - S1828
  • [40] Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13. 1st Edition
    不详
    ANTICANCER RESEARCH, 2021, 41 (06) : 3211 - 3212
12345